Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Updating, Report Card, Stem Cell/Regenerative Medicine Universe Earnings to Date

Adding to our Report Card blog of 11/15/10:

An earnings release is a ‘report card’ of sorts for public stem cell and regenerative medicine companies. Yet, the current LPS (loss per share) standings reflect the industries investing status. So far, only … OSIR this quarter reported a positive net income.

By analyzing this comparison, investors can begin to gauge the financial health versus the scientific opportunity of stem cell research and whether or not it deserves their investment.

For the quarter ending 9/30/10, earnings continue to be announced:

  • CYTX reported a net loss of $10.4M, or $(0.23) per share;
  • STEM reported a net loss of $5.552M, or $(0.04) per share;
  • BMTI reported a net loss of $7.8M, or ($0.29) per share;
  • TNGN reported a net loss of $6.7M or (0.54) per share;
  • GERN reported a net loss of $18.3M or $(0.19) per share;
  • KOOL reported Q1/11 net loss of $68K or ($0.00) per share;
  • OSIR reported net income of $4.5M or $0.14 per share;                                                             
  • ASTM’s reported Q1/11 net loss of $5.83M or ($0.21) per share;
  • ATHX reported a net loss of $3.75M or ($0.19) per share;
  • ACTC.OB reported a net loss of $1.9M or ($0.00) per share;
  • OPXA reported a net loss of $1.29M or ($0.07) per share;
  • PSTI reported a net loss of $1.67M or ($0.08) per share;
  • NBS reported a net loss of $7.14M or ($0.13) per share;
  • ISCO.OB reported a net loss of $2.9M or ($0.04) per share.

Newest:

  • BTX reported a net loss of $4.66M or ($0.11) per share;
  • CUR reported a net loss of $3.9M or ($0.09) per share.